INPWT on Wound Complications & Clinical Outcomes After Lower Extremity Sarcoma Surgery Preop Radiation Therapy Patients
Launched by DR. J. WERIER · Jun 1, 2017
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different types of dressings applied after surgery can affect healing in patients with soft tissue sarcoma in the legs. Soft tissue sarcoma is a type of aggressive cancer, and patients often face complications like infections after surgery, which can lead to longer hospital stays and additional surgeries. The researchers want to see if using a special vacuum dressing, instead of a standard one, can help reduce these complications and improve patients' recovery.
To participate in the trial, you need to be at least 18 years old and have a confirmed diagnosis of lower extremity soft tissue sarcoma. You should also be planning to receive radiation therapy before your surgery and be eligible for a type of surgery that allows for direct closure of the wound. If you join the study, you will be randomly assigned to receive either the standard dressing or the vacuum dressing after your surgery. The hope is that this research will lead to better healing, shorter hospital stays, and overall improved quality of life for patients undergoing treatment for this type of cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients 18 years of age and older and are able to provide written consent.
- • Patients with lower extremity soft tissue sarcoma confirmed by tissue pathology.Each patient must have local cross sectional imaging (CT or MRI) and a staging CT chest.
- • Patients eligible for treatment with preoperative radiation therapy followed by limb salvage surgery.
- • Patients for which a primary closure must be attained at the time of surgery.
- • Patient must be available for postoperative follow-up at the treating center.
- Exclusion Criteria:
- • Patients who are less than 18 years of age.
- • Patients with a benign disease or with prior radiation to the anatomic region in the remote past (not associated with current treatment radiation plans).
- • Patients who underwent surgical amputation
- • Patients in which primary closure was not achieved (including free flaps and split thickness skin grafts).
- • Patients with a life expectancy less than 120 days.
- • Patients who have an allergy or sensitivity to adhesive dressings.
About Dr. J. Werier
Dr. J. Werier is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With extensive expertise in clinical development, Dr. Werier oversees a range of innovative trials across various therapeutic areas, ensuring adherence to regulatory standards and ethical guidelines. By fostering collaboration among multidisciplinary teams and leveraging cutting-edge methodologies, Dr. Werier aims to accelerate the translation of scientific discoveries into effective treatments, ultimately enhancing the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ottawa, Ontario, Canada
Montréal, Quebec, Canada
Patients applied
Trial Officials
Joel Werier
Principal Investigator
Surgeon
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials